|
14 Mar 2025 |
Jyothy Labs
|
Consensus Share Price Target
|
330.80 |
490.23 |
- |
48.20 |
buy
|
|
|
|
|
11 Mar 2025
|
Jyothy Labs
|
Geojit BNP Paribas
|
330.80
|
395.00
|
333.90
(-0.93%)
|
19.41 |
Buy
|
|
|
|
|
01 Feb 2025
|
Jyothy Labs
|
Axis Direct
|
330.80
|
450.00
|
415.70
(-20.42%)
|
36.03 |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
31 Jan 2025
|
Jyothy Labs
|
Sharekhan
|
330.80
|
490.00
|
398.40
(-16.97%)
|
48.13 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q3FY25 performance was muted with revenue growing by just 4%, while a ~110 bps y-o-y decline in OPM led to 4% y-o-y decline in PAT.
|
|
04 Dec 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
330.80
|
496.00
|
411.15
(-19.54%)
|
49.94 |
Buy
|
|
|
|
|
13 Nov 2024
|
Jyothy Labs
|
Axis Direct
|
330.80
|
500.00
|
436.10
(-24.15%)
|
51.15 |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
12 Nov 2024
|
Jyothy Labs
|
Sharekhan
|
330.80
|
575.00
|
441.35
(-25.05%)
|
73.82 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q2FY2025 performance was muted with revenue and PAT remaining flat y-o-y. OPM at 18.9% rose by 38 bps y-o-y.
|
|
12 Nov 2024
|
Jyothy Labs
|
Motilal Oswal
|
330.80
|
500.00
|
441.35
(-25.05%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported flat sales YoY (miss) in 2QFY25. It posted a five-year CAGR of 10%. Volume growth was at 3%, on account of a high base.
|
|
13 Aug 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
330.80
|
645.00
|
548.10
(-39.65%)
|
94.98 |
Accumulate
|
|
|
|
|
26 Jul 2024
|
Jyothy Labs
|
Axis Direct
|
330.80
|
600.00
|
548.45
(-39.68%)
|
81.38 |
Buy
|
|
|
We maintain our long-term BUY rating on the stock.
|
|
25 Jul 2024
|
Jyothy Labs
|
Motilal Oswal
|
330.80
|
565.00
|
547.70
(-39.60%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported a revenue growth of 8% YoY (in line) in 1QFY25. It delivered a volume growth of 11% and continued to focus on volume-led growth to gain market share across categories.
|
|
25 Jul 2024
|
Jyothy Labs
|
Sharekhan
|
330.80
|
655.00
|
547.70
(-39.60%)
|
98.00 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q1FY2025 operating performance was in line with our expectation with revenues growing by 8% (versus expectation of 8.5%) while OPM stood at 18% (versus expectation of 17.9%).
|
|
25 Jul 2024
|
Jyothy Labs
|
ICICI Securities Limited
|
330.80
|
640.00
|
547.70
(-39.60%)
|
93.47 |
Buy
|
|
|
JYL’s Q1FY25 volume growth of 11% YoY is a material outperformance vs peers on a higher base as it continues to focus on direct distribution expansion, innovation, new SKUs coupled with continued investment behind the brands.
|
|
29 May 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
330.80
|
478.00
|
413.25
(-19.95%)
|
Target met |
Accumulate
|
|
|
|
|
16 May 2024
|
Jyothy Labs
|
Axis Direct
|
330.80
|
500.00
|
446.40
(-25.90%)
|
Target met |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
09 Mar 2024
|
Jyothy Labs
|
Axis Direct
|
330.80
|
475.00
|
429.50
(-22.98%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 475/share, implying an upside of 10% from the CMP.
|
|
23 Feb 2024
|
Jyothy Labs
|
Sharekhan
|
330.80
|
590.00
|
467.05
(-29.17%)
|
Target met |
Buy
|
|
|
|
|
23 Feb 2024
|
Jyothy Labs
|
Sharekhan
|
330.80
|
590.00
|
475.65
(-30.45%)
|
Target met |
Buy
|
|
|
|
|
01 Feb 2024
|
Jyothy Labs
|
Axis Direct
|
330.80
|
565.00
|
508.20
(-34.91%)
|
Target met |
Buy
|
|
|
With a 10% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
01 Feb 2024
|
Jyothy Labs
|
Motilal Oswal
|
330.80
|
500.00
|
508.20
(-34.91%)
|
Target met |
Neutral
|
|
|
|
|
16 Nov 2023
|
Jyothy Labs
|
Geojit BNP Paribas
|
330.80
|
405.00
|
439.20
(-24.68%)
|
Target met |
Sell
|
|
|
|